Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: A trial of the NCIC Clinical Trials Group

Journal of Clinical Oncology

Volumn 29, Issue 24, 2011, Pages 3278-3285

  Oza, Amit M ^a   Elit, Laurie ^b   Tsao, Ming Sound ^a   Kamel Reid, Suzanne ^a   Biagi, Jim ^c   Provencher, Diane Michele ^e   Gotlieb, Walter H ^f   Hoskins, Paul J ^g   Ghatage, Prafull ^h   Tonkin, Katia S ⁱ   Mackay, Helen J ^a   Mazurka, John ^b   Sederias, Joana ^d   Ivy, Percy ^j   Dancey, Janet E ^d   Eisenhauer, Elizabeth A ^d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c Cancer Centre of Southeastern Ontario   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

^h TOM BAKER CANCER CENTRE   (Canada)

ⁱ CROSS CANCER INSTITUTE   (Canada)

^j NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; GESTAGEN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN SERINE THREONINE KINASE; TEMSIROLIMUS;

ABDOMINAL PAIN; ACNE; ADENOSQUAMOUS CARCINOMA; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASYMPTOMATIC DISEASE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLEAR CELL CARCINOMA; CONTROLLED STUDY; COUGHING; DESQUAMATION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRY SKIN; DYSPNEA; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; EPISTAXIS; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MIXED TUMOR; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; MYALGIA; NAIL; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RECURRENT CANCER; SENSORY NEUROPATHY; SIDE EFFECT; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; XEROSTOMIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; RECURRENCE; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 80052010923     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.1578     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59:225-249, 2009
2. Emons G, Heyl W: Hormonal treatment of endometrial cancer. J Cancer Res Clin Oncol 126: 619-623, 2000
3. Lentz SS, Brady MF, Major FJ, et al: High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 14:357-361, 1996
4. Podratz KC, O'Brien PC, Malkasian GD Jr, et al: Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol 66:106-110, 1985
5. Quinn MA, Cauchi M, Fortune D: Endometrial carcinoma: Steroid receptors and response to medroxyprogesterone acetate. Gynecol Oncol 21:314-319, 1985
6. Thigpen JT, Brady MF, Alvarez RD, et al: Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: A dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17:1736-1744, 1999
7. Bonte J, Decoster JM, Ide P, et al: Hormonoprophylaxis and hormonotherapy in the treatment of endometrial adenocarcinoma by means of medroxyprogesterone acetate. Gynecol Oncol 6:60-75, 1978
8. Bonte J, Ide P, Billiet G, et al: Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma. Gynecol Oncol 11:140-161, 1981
9. Slavik M, Petty WM, Blessing JA, et al: Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: A Gynecologic Oncology Group study. Cancer Treat Rep 68:809-811, 1984
10. Swenerton KD, White GW, Boyes DA: Treatment of advanced endometrial carcinoma with tamoxifen. N Engl J Med 301:105, 1979
11. Thigpen T, Brady MF, Homesley HD, et al: Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 19:364-367, 2001
12. Bellone S, Shah HR, McKenney JK, et al: Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole. Am J Obstet Gynecol 199:e7-e10, 2008
13. Ma BB, Oza A, Eisenhauer E, et al: The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers: A study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 14:650-658, 2004
14. Rose PG, Brunetto VL, VanLe L, et al: A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 78:212-216, 2000
15. Fleming GF, Brunetto VL, Cella D, et al: Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 22:2159-2166, 2004
16. Hoskins PJ, Swenerton KD, Pike JA, et al: Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: A phase II study. J Clin Oncol 19:4048-4053, 2001
17. Price FV, Edwards RP, Kelley JL, et al: A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: Preliminary report. Semin Oncol 24: S15-78-S15-82, 1997 (suppl 15)
18. HumberCE, Tierney JF,SymondsRP, et al:Chemotherapy for advanced, recurrent or metastatic endometrial cancer: A systematic review of Cochrane collaboration. Ann Oncol 18:409-420, 2007
19. Catasus L, D'Angelo E, Pons C, et al: Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations. Mod Pathol 23:694-702, 2010
20. Cohen Y, Shalmon B, Korach J, et al: AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma. Gynecol Oncol 116: 88-91, 2010
21. Salvesen HB, Carter SL, Mannelqvist M, et al: Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A 106:4834-4839, 2009
22. Lu KH, Wu W, Dave B, et al: Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clin Cancer Res 14:2543-2550, 2008
23. Catasus L, Gallardo A, Cuatrecasas M, et al: Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol 22:522-529, 2009
24. Latta E, Chapman WB: PTEN mutations and evolving concepts in endometrial neoplasia. Curr Opin Obstet Gynecol 14:59-65, 2002
25. Kanamori Y, Kigawa J, Itamochi H, et al: Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res 7:892-895, 2001
26. Neshat MS, Mellinghoff IK, Tran C, et al: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 98:10314-10319, 2001
27. Podsypanina K, Lee RT, Politis C, et al: An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A 98:10320-10325, 2001
28. Mackay HJ, Gallinger S, Tsao MS, et al: Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: Results from studies of the NCIC Clinical Trials Group (NCIC CTG). Eur J Cancer 46:1365-1373, 2010
29. Whang YE, Wu X, Sawyers CL: Identification of a pseudogene that can masquerade as a mutant allele of the PTEN/MMAC1 tumor suppressor gene. J Natl Cancer Inst 90:859-861, 1998
30. Bussaglia E, del Rio E, Matias-Guiu X, et al: PTEN mutations in endometrial carcinomas: A molecular and clinicopathologic analysis of 38 cases. Hum Pathol 31:312-317, 2000
31. Risinger JI, Hayes K, Maxwell GL, et al: PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 4:3005-3010, 1998
32. Dancey JE: Clinical development of mammalian target of rapamycin inhibitors. Hematol Oncol Clin North Am 16:1101-1114, 2002
33. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007
34. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
35. Jänne PA, Borras AM, Kuang Y, et al: A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 12:751-758, 2006
36. Konopka B, Paszko Z, Janiec-Jankowska A, et al: Assessment of the quality and frequency of mutations occurrence in PTEN gene in endometrial carcinomas and hyperplasias. Cancer Lett 178:43-51, 2002